Skip to main content

Advertisement

Table 3 Multiple generalised linear regression analysis of the determinants of total mean monthly costs (US$)

From: Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings

Variables Value % change from referent p-value
Time period relative to ART initiation (months) -4 to 4 384 (321 to 459) 80% <0.001
  4 to 12 238 (204 to 277) 12% 0.158
  12 to 24 Referent
  24 to 48 222 (182 to 270) 4% 0.705
Baseline CD4 count (cells/µL) 0 to 49 193 (164 to 227) -10% 0.228
  50 to 199 Referent
Current CD4 count (cells/µL) 0 to 49 352 (290 to 426) 65% <0.001
  50 to 199 Referent
  200 to 349 190 (161 to 223) -11% 0.16
  350 to 499 166 (141 to 195) -22% 0.002
  ≥500 158 (123 to 202) -26% 0.017
Baseline viral load (copies/ml) <100 000 Referent
  ≥100 000 220 (195 to 248) 3% 0.601
Current viral load (copies/ml) <400 Referent
  400 to 9 999 219 (191 to 250) 3% 0.717
  10 000 to 99 999 195 (164 to 232) -8% 0.317
  ≥100 000 249 (209 to 296) 17% 0.082
Overall adherence <42% 264 (235 to 297) 24% <0.001
  42 to 74% 263 (233 to 295) 23% 0.001
  75 to 92% 244 (218 to 273) 14% 0.019
  ≥92% Referent
ARV regimen First line Referent
  Second line 409 (255 to 656) 92% 0.007
NNRTI in first line Nevirapine 197 (182 to 213) -8% 0.042
  Efavirenz Referent
Duration of CD4 count monitoring (months) ≤6 181 (161 to 204) -15% 0.008
  >6 Referent
Sex Male 206 (188 to 226) -3% 0.463
  Female Referent
Age at starting ART (years) <25 194 (164 to 230) -9% 0.282
  25 to 50 Referent
  >50 230 (194 to 271) 8% 0.384
Referent cost   213 (178 to 256) NA NA